Sun Pharma

    SUNPHARMA
    Pharma
    ₹1835.00
    price as of 15/9/2026, 6:27:55 pm

    Market cap ₹4.40 L Cr

    P/E
    36.39
    Day range
    ₹1,828.00 – ₹1,856.80
    52-week range
    ₹1,548.00 – ₹2,046.90
    Volume
    14.37 L
    Open
    ₹1,854.60
    Prev close
    ₹1,840.00

    Key metrics

    P/E (TTM)
    36.7
    EPS (TTM)
    ₹50.44
    ROE (FY26)
    14.8%
    ROCE (latest year)
    21%
    Dividend yield
    0.86%

    Charts & trends

    From company filings. Amounts in ₹ crore.

    Revenue 3Y CAGR
    +10.0%
    Profit 3Y CAGR
    +10.6%
    Revenue YoY (Jun 2026)
    +10.5%
    Profit YoY (Jun 2026)
    +26.5%
    Operating margin
    29.0%
    Net margin
    19.0%

    Revenue, profit & margin - quarterly

    Bars in ₹ crore (a loss shows red); line is operating margin

    Sep 2023Mar 2024Sep 2024Mar 2025Sep 2025Jun 20260 Cr4.0K Cr8.0K Cr12.0K Cr16.0K Cr0%8%16%24%32%
    • Revenue
    • Net profit
    • Operating margin

    Who owns the company

    Shareholding as of Jun 2026

    • Promoter
    • DII
    • FII
    • Public
    • Government

    Cash flows

    Where cash came from and went, by fiscal year (₹ crore)

    Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026-15.0KCr-7.5K Cr0 Cr7.5K Cr15.0K Cr
    • Operating
    • Investing
    • Financing
    • Free cash flow

    Return on equity

    Net profit over shareholders' equity, by fiscal year

    FY17FY18FY19FY20FY21FY22FY23FY24FY25FY260%6%12%18%24%15%

    Equity vs debt

    Shareholders' equity against borrowings (₹ crore); line is debt-to-equity

    Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 20260 Cr25.0K Cr50.0K Cr75.0K Cr1.0L Cr0.0x0.1x0.1x0.2x0.3x
    • Equity
    • Debt
    • Debt / equity

    Financial statements

    ₹ Crore
    Quarterly results, oldest period first, figures in rupees crore
    Line itemSep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
    Sales12,19212,38111,98312,65313,29113,67512,95913,85114,47815,52114,61215,300
    Expenses9,0138,9048,9489,0459,3529,6669,2439,5509,95110,57210,65810,882
    Operating Profit3,1793,4773,0353,6083,9394,0093,7164,3024,5274,9483,9544,418
    OPM %26%28%25%29%30%29%29%31%31%32%27%29%
    Other Income294180504533354149251-35447089458520
    Interest49357462695249751007886100
    Depreciation633622650655626631664701730732775739
    Profit before tax2,7913,0002,8163,4243,5983,4763,2543,1734,1684,2273,5514,099
    Tax %14%14%5%16%16%16%34%27%25%20%23%29%
    Net Profit2,3852,5612,6592,8613,0372,9132,1542,2933,1253,3812,7102,901
    EPS in Rs₹9.90₹10.52₹11.06₹11.82₹12.67₹12.10₹8.96₹9.50₹13.00₹14.04₹11.31₹12.06

    From company filings, updated 15 Sept 2026. Consolidated figures where the company reports them.Information only, not investment advice.

    Working-capital cycle

    Debtor Days97

    -2 days since Mar 2021

    Inventory Days363

    -15 days since Mar 2021

    Days Payable232

    +65 days since Mar 2021

    Cash Conversion Cycle228

    -82 days since Mar 2021

    Working Capital Days54

    +3 days since Mar 2021

    Strengths, risks & growth

    Sun Pharmaceutical Industries Ltd is engaged in the business of manufacturing, developing and marketing a wide range of branded and generic formulations and Active Pharma Ingredients (APIs). The company and its subsidiaries has various manufacturing facilities spread across the world with trading and other incidental and related activities extending to global market. [1] It is the largest pharmaceutical company in India. [2]

    Strengths

    • Company is almost debt free.
    • Company has been maintaining a healthy dividend payout of 34.1%

    Risks

    • The company has delivered a poor sales growth of 11.8% over past five years.

    Compounded Sales Growth

    10 Years
    +7%
    5 Years
    +12%
    3 Years
    +10%
    TTM
    +11%

    Compounded Profit Growth

    10 Years
    +10%
    5 Years
    +17%
    3 Years
    +13%
    TTM
    +10%

    Stock Price CAGR

    10 Years
    +9%
    5 Years
    +19%
    3 Years
    +17%
    1 Year
    +15%

    Return on Equity

    10 Years
    +14%
    5 Years
    +16%
    3 Years
    +16%
    Last Year
    +16%

    Strengths and risks are a machine-generated checklist, not advice; growth is compounded annually over each period.

    Shareholding pattern

    Percentage of shares held by each category at each quarter end
    HolderSept 2025Dec 2025Mar 2026Jun 2026Change
    Promoter54.48%54.48%54.48%54.48%0.00 pp
    FII16.55%16.12%15.94%14.54%-1.40 pp
    DII20.12%20.72%21.00%22.06%+1.06 pp
    Government0.11%0.11%0.11%0.11%0.00 pp
    Public8.72%8.57%8.48%8.81%+0.33 pp

    Filed with NSE for Jun 2026: promoters 54.48%, public 45.52% · XBRL filing

    Analysts & fund holdings

    94%
    94% recommend buy
    31 analysts cover the stock
    Valuation vs Pharmaceuticals
    P/E36.4 vs 46.4
    Sector P/B5.84
    Beta0.84

    Who holds the shares, quarter by quarter

    Mutual funds 12.84% (+0.88 pp)
    Mar 25
    Jun 25
    Sept 25
    Dec 25
    Mar 26
    Jun 26
    • Promoters54.5%
    • Foreign institutions14.5%
    • Mutual funds12.8%
    • Insurance7.0%
    • Other domestic institutions2.3%
    • Retail4.4%
    • Others4.4%
    Mutual funds holding the most
    Fund% of company% of fund3-month change
    ICICI Pru Value Fund0.60%4.55%-0.24 pp
    ICICI Pru Aggressive Hybrid Fund0.43%3.73%+0.13 pp
    ICICI Pru Large Cap Fund0.39%2.24%-0.27 pp
    HDFC Balanced Advantage Fund0.36%1.54%+0.08 pp
    Nippon India Large Cap Fund0.27%2.26%-0.56 pp

    Scorecard

    Performance
    Avg
    Valuation
    High
    Growth
    Low
    Profitability
    High
    Entry point
    Good
    Red flags
    Low

    Analyst coverage, holdings and scorecard from market data; not a recommendation by Parasram India.

    Risk & trend

    From 248 daily sessions to 11 Sept 2026.

    Computed

    Risk

    Volatility (1Y)
    19.3%
    Downside volatility
    18.9%
    Worst 5% of days
    2.0%
    Average of that tail
    2.8%
    Max drawdown (1Y)
    13.2%
    Below its peak
    8.1%

    Against the market

    Beta vs Nifty 50
    0.48
    Correlation
    0.33
    Relative strength (3M)
    +3.8%
    ATR (14)
    1.8%

    Return

    Return 1M
    -4.8%
    Return 3M
    +1.9%
    Return 6M
    +1.5%
    Return 1Y
    —
    vs 200-day average
    +1.9%

    Momentum

    RSI (14)
    34.0
    MACD histogram
    -8.20
    Stochastic %K
    4.0
    ADX (14)
    19.0
    +DI / −DI
    12.1 / 23.0
    Money flow index
    29.2

    Participation

    Delivery (20d avg)
    64.3%
    vs its 60-day baseline
    +1.2 pts
    Volume vs 20-day
    -0.1σ
    Close vs day's VWAP
    -0.2%
    52-week position
    61 / 100

    These describe what this stock's price has already done. They are not forecasts, signals or recommendations, and a dash means the figure was withheld for want of enough history rather than being zero.

    Financial quality

    From consolidated statements to 30 Jun 2026.

    Computed

    Computed from filed statements, not filed themselves. A dash means an input was absent, and the score counts only the criteria that could actually be tested.

    Corporate actions

    • dividend
      ₹5.00

      Dividend - Rs 5 Per Share

      7 Jul 2026
      ex-date
    • dividend
      ₹11.00

      Interim Dividend - Rs 11 Per Share

      5 Feb 2026
      ex-date
    • dividend
      ₹5.50

      Dividend - Rs 5.50 Per Share

      7 Jul 2025
      ex-date
    • dividend
      ₹10.50

      Interim Dividend - Rs 10.50 Per Share

      6 Feb 2025
      ex-date
    • dividend
      ₹5.00

      Dividend - Rs 5 Per Share

      12 Jul 2024
      ex-date
    • dividend
      ₹8.50

      Interim Dividend - Rs 8.50 Per Share

      9 Feb 2024
      ex-date
    • dividend
      ₹4.00

      Dividend - Rs 4 Per Share

      28 Jul 2023
      ex-date
    • dividend
      ₹7.50

      Interim Dividend - Rs 7.50 Per Share

      8 Feb 2023
      ex-date
    • dividend
      ₹3.00

      Dividend - Rs 3 Per Share

      19 Aug 2022
      ex-date
    • dividend
      ₹7.00

      Interim Dividend - Rs 7 Per Share

      9 Feb 2022
      ex-date
    • dividend
      ₹2.00

      Annual General Meeting/Dividend - Rs 2 Per Share

      23 Aug 2021
      ex-date
    • dividend
      ₹5.50

      Interim Dividend - Rs 5.50 Per Share

      9 Feb 2021
      ex-date
    • dividend
      Not available — not reported in this filing

      Annual General Meeting/Dividend - Re 1 Per Share

      19 Aug 2020
      ex-date
    • dividend
      ₹3.00

      Interim Dividend - Rs 3 Per Share

      17 Feb 2020
      ex-date
    • dividend
      ₹2.75

      Annual General Meeting/Dividend - Rs 2.75 Per Share

      20 Aug 2019
      ex-date
    • dividend
      ₹2.00

      Annual General Meeting/Dividend Rs 2 Per Share

      17 Sept 2018
      ex-date
    • dividend
      ₹3.50

      Annual General Meeting/Dividend - Rs 3.50 Per Share

      18 Sept 2017
      ex-date
    • dividend
      Not available — not reported in this filing

      Annual General Meeting/Dividend Re 1/- Per Share

      8 Sept 2016
      ex-date
    • buyback
      Not available — not reported in this filing

      Buy Back

      14 Jul 2016
      ex-date
    • dividend
      ₹3.00

      Annual General Meeting/ Dividend - Rs 3/- Per Share

      21 Oct 2015
      ex-date

    Company announcements

    Company Update
    Intimation Under Regulation 30 Of SEBI LODR

    As attached

    Company Update
    Incorporation Of A Subsidiary Company

    Incorporation of wholly owned subsidiary of the Company in the International Financial Services Centre at GIFT City, Gandhinagar, Gujarat, India

    Company UpdatePrice-sensitive
    Announcement under Regulation 30 (LODR)-Credit Rating

    International Credit Ratings

    Company Update
    Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    Intimation of Schedule of Analyst/Institutional Investor Meeting

    Company Update
    Announcement under Regulation 30 (LODR)-Press Release / Media Release

    Sun Pharma participates in White House Signing Ceremony highlighting U.S. Medicines Pricing and Access Commitments

    Company Update
    Announcement under Regulation 30 (LODR)-Newspaper Publication

    Newspaper Advertisements about Postal Ballot/E-voting

    AGM/EGM
    Shareholder Meeting / Postal Ballot-Notice of Postal Ballot

    Notice of Postal Ballot/E-voting

    Company Update
    Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    Intimation of Schedule of Analyst/Institutional Investor Meeting

    Company Update
    Update On Lipitor Antitrust Litigation

    Update on Lipitor Antitrust Litigation

    Company Update
    Receipt Of No-Objection Letters From The Stock Exchanges For Reclassification Of Promoter Group

    Receipt of No-objection letters from the Stock Exchanges for Reclassification of Promoter Group

    Company Update
    Announcement under Regulation 30 (LODR)-Earnings Call Transcript

    Q1FY27 Earnings Call Transcript

    Company Update
    Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    Intimation of Schedule of Analyst/Institutional Investor Meeting

    Company UpdatePrice-sensitive
    Announcement under Regulation 30 (LODR)-Credit Rating

    Update on Credit Rating

    Company Update
    Announcement under Regulation 30 (LODR)-Newspaper Publication

    Newspaper Advertisement

    Company Update
    Voting Results And Scrutinizer Report Of 34Th AGM Held On 31 July 2026

    Voting Results for 34th AGM

    Filed with BSE (scrip 524715); the last 45 days. Documents open at bseindia.com.

    Documents

    Annual reports

    Earnings calls

    Credit ratings

    Documents open at BSE or the rating agency that issued them.

    Sourced from the company's NSE XBRL filing dated 1 Feb 2025 (unaudited). View the source filing. Figures are as filed and are not investment advice.